Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: Comparison with metoprolol therapy

Journal of Nuclear Medicine

Volumn 44, Issue 10, 2003, Pages 1604-1611

  Toyama, Takuji ^a   Hoshizaki, Hiroshi ^a   Seki, Ryotaro ^a   Isobe, Naoki ^a   Adachi, Hitoshi ^a   Naito, Shigeto ^a   Oshima, Shigeru ^a   Taniguchi, Koichi ^a  

^a GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

Author keywords

123I MIBG imaging; Carvedilol; Dilated cardiomyopathy; Metoprolol

Indexed keywords

3 IODOBENZYLGUANIDINE I 123; CARVEDILOL; METOPROLOL; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROPANOLAMINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART FUNCTION; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MEDIASTINUM; PRIORITY JOURNAL; SYMPATHETIC FUNCTION; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE; TREATMENT OUTCOME; ADRENERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; INNERVATION; MIDDLE AGED; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADRENERGIC ANTAGONISTS; ADULT; AGED; CARBAZOLES; CARDIOMYOPATHY, DILATED; FEMALE; HEART VENTRICLES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0642341626     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-243
2. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIC-II): a randomized trial. Lancet. 1999;353:9-13.
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007
5. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355
6. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
7. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure N Engl J Med. 2001;344:1659-1667.
8. Sanderson JE, Chan SK, Yip G, et al Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-1528.
9. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-2651
10. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Cas LD. Differential effects of beta-blockers in patients with heart failure a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol Circulation. 2000;102:546-551.
11. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart Circulation. 1996;94:2817-2825.
12. Schofer J, Spielmann R, Schbert A, Weber K, Schluter M. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic system disintegrity in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol. 1988;12:1252-1258
13. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477
14. Sahn DJ, DeMaria A, Kissio J, Weyman A Recommendations regarding quantitation in M-mode echocardiography: result of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083
15. Teicholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976;37:7-11.
16. Alderman J, Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation. 1985;71:854-857.
17. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy Circulation. 1991;84:2426-2441
18. Yamada T, Fukunami M, Ohmon M, et al Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? J Am Coll Cardiol 1993;21:628-633.
19. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463.
20. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
21. Maisel AS Beneficial effects of metoprolol treatment in congestive heart failure reversal of sympathetic-induced alterations of immunologic function. Circulation 1994;90:1774-1780
22. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17:8-16.
23. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agent. Am J Cardiol. 1993;71:12C-22C.
24. Ruffolo RR, Gallai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38(suppl 2):S82-S88.
25. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Sker L, et al Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest. 1992;70(suppl 1):S105-S113.
26. Bristow MR, Larrabee P, Minobe W. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.
27. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
28. Cargnoni A, Ceconi C, Berriocchi P, et al Reduction of oxidative stress by carvedilol, role in maintenance of ischaemic myocardium viability Cardiovasc Res. 2000;18:556-566.
29. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-2089.
30. Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608-615.
31. Bennett SK, Smith MF, Gottlieb SS, Fisher ML, Bacharach SL, Dilsizian V Effect of metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2002;89:1431-1434.